158 related articles for article (PubMed ID: 37342994)
21. A new target for gold(I) compounds: glutathione-S-transferase inhibition by auranofin.
De Luca A; Hartinger CG; Dyson PJ; Lo Bello M; Casini A
J Inorg Biochem; 2013 Feb; 119():38-42. PubMed ID: 23183361
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of erythrocyte selenium-glutathione peroxidase by auranofin analogues and metabolites.
Roberts JR; Shaw CF
Biochem Pharmacol; 1998 Apr; 55(8):1291-9. PubMed ID: 9719485
[TBL] [Abstract][Full Text] [Related]
23. Formation of a cationic gold(I) complex and disulfide by oxidation of the antiarthritic gold drug auranofin.
Mohamed AA; Chen J; Bruce AE; Bruce MR; Krause Bauer JA; Hill DT
Inorg Chem; 2003 Apr; 42(7):2203-5. PubMed ID: 12665352
[TBL] [Abstract][Full Text] [Related]
24. Repurposing Auranofin and Evaluation of a New Gold(I) Compound for the Search of Treatment of Human and Cattle Parasitic Diseases: From Protozoa to Helminth Infections.
Feng L; Pomel S; Latre de Late P; Taravaud A; Loiseau PM; Maes L; Cho-Ngwa F; Bulman CA; Fischer C; Sakanari JA; Ziniel PD; Williams DL; Davioud-Charvet E
Molecules; 2020 Nov; 25(21):. PubMed ID: 33139647
[TBL] [Abstract][Full Text] [Related]
25. Ligand Exchange/Scrambling Study of Gold(I)-Phosphine Complexes in the Solid Phase by DESI-MS Analysis.
Kazimi SGT; Iqbal MS; Mulligan CC; Frank Shaw C; Iram F; Stelmack AR; Campbell IS
J Am Soc Mass Spectrom; 2019 Nov; 30(11):2289-2296. PubMed ID: 31502222
[TBL] [Abstract][Full Text] [Related]
26. Induction of the 32-kD human stress protein by auranofin and related triethylphosphine gold analogs.
Caltabiano MM; Poste G; Greig RG
Biochem Pharmacol; 1988 Nov; 37(21):4089-93. PubMed ID: 3190747
[TBL] [Abstract][Full Text] [Related]
27. Mechanistic Insights Into the Anticancer Properties of the Auranofin Analog Au(PEt
Tolbatov I; Cirri D; Marchetti L; Marrone A; Coletti C; Re N; La Mendola D; Messori L; Marzo T; Gabbiani C; Pratesi A
Front Chem; 2020; 8():812. PubMed ID: 33195032
[TBL] [Abstract][Full Text] [Related]
28. Anti-Staphylococcal Activity of the Auranofin Analogue Bearing Acetylcysteine in Place of the Thiosugar: An Experimental and Theoretical Investigation.
Chiaverini L; Pratesi A; Cirri D; Nardinocchi A; Tolbatov I; Marrone A; Di Luca M; Marzo T; La Mendola D
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458776
[TBL] [Abstract][Full Text] [Related]
29. New Variations on the Theme of Gold(III) C
Carboni S; Zucca A; Stoccoro S; Maiore L; Arca M; Ortu F; Artner C; Keppler BK; Meier-Menches SM; Casini A; Cinellu MA
Inorg Chem; 2018 Dec; 57(23):14852-14865. PubMed ID: 30457328
[TBL] [Abstract][Full Text] [Related]
30. Strategies for the design of analogs of auranofin endowed with anticancer potential.
Vitali V; Massai L; Messori L
Expert Opin Drug Discov; 2024 Jul; 19(7):855-867. PubMed ID: 38803122
[TBL] [Abstract][Full Text] [Related]
31. A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition.
Ilari A; Baiocco P; Messori L; Fiorillo A; Boffi A; Gramiccia M; Di Muccio T; Colotti G
Amino Acids; 2012 Feb; 42(2-3):803-11. PubMed ID: 21833767
[TBL] [Abstract][Full Text] [Related]
32. Gold Complexes for Therapeutic Purposes: an Updated Patent Review (2010-2015).
Nardon C; Pettenuzzo N; Fregona D
Curr Med Chem; 2016; 23(29):3374-3403. PubMed ID: 27142288
[TBL] [Abstract][Full Text] [Related]
33. Diverse in vitro and in vivo anti-inflammatory effects of trichlorido-gold(III) complexes with N6-benzyladenine derivatives.
Křikavová R; Hošek J; Suchý P; Vančo J; Trávníček Z
J Inorg Biochem; 2014 May; 134():92-9. PubMed ID: 24584156
[TBL] [Abstract][Full Text] [Related]
34. A new structural transition of serum albumin dependent on the state of Cys34. Detection by 1H-NMR spectroscopy.
Christodoulou J; Sadler PJ; Tucker A
Eur J Biochem; 1994 Oct; 225(1):363-8. PubMed ID: 7925457
[TBL] [Abstract][Full Text] [Related]
35. Cyclic (Alkyl)(Amino)Carbene (CAAC) Gold(I) Complexes as Chemotherapeutic Agents.
Proetto MT; Alexander K; Melaimi M; Bertrand G; Gianneschi NC
Chemistry; 2021 Feb; 27(11):3772-3778. PubMed ID: 33090571
[TBL] [Abstract][Full Text] [Related]
36. The cellular and molecular pharmacology of auranofin and related gold complexes.
Crooke ST; Snyder RM
Scand J Rheumatol Suppl; 1986; 63():1-18. PubMed ID: 3474775
[TBL] [Abstract][Full Text] [Related]
37. Comparative (13)C and (31)P NMR studies of the ligand exchange reactions of auranofin with ergothionine, imidazolidine-2-thione and diazinane-2-thione.
Isab AA; Ahmad S
J Inorg Biochem; 2002 Jan; 88(1):53-60. PubMed ID: 11750025
[TBL] [Abstract][Full Text] [Related]
38. Gold(I)-triphenylphosphine complexes with hypoxanthine-derived ligands: in vitro evaluations of anticancer and anti-inflammatory activities.
Křikavová R; Hošek J; Vančo J; Hutyra J; Dvořák Z; Trávníček Z
PLoS One; 2014; 9(9):e107373. PubMed ID: 25226034
[TBL] [Abstract][Full Text] [Related]
39. Cellular association, intracellular distribution, and efflux of auranofin via sequential ligand exchange reactions.
Snyder RM; Mirabelli CK; Crooke ST
Biochem Pharmacol; 1986 Mar; 35(6):923-32. PubMed ID: 3082334
[TBL] [Abstract][Full Text] [Related]
40. Reactions of model proteins with aurothiomalate, a clinically established gold(I) drug: The comparison with auranofin.
Darabi F; Marzo T; Massai L; Scaletti F; Michelucci E; Messori L
J Inorg Biochem; 2015 Aug; 149():102-7. PubMed ID: 25865000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
